title: LK or IGF1R: When selectivity hurts.
authors.affiliation: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Puzanov
authors.affiliation: Science Writer, Atlanta, Georgia, USA.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Hess
mesh_terms: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017526:Receptor, IGF Type 1; D017451:Receptors, Somatomedin / Q000235:genetics / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C000597236:IGF1R protein, human; D017451:Receptors, Somatomedin; D011505:Protein-Tyrosine Kinases; D017526:Receptor, IGF Type 1